154 related articles for article (PubMed ID: 36594188)
1. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
2. Treatment of children with refractory/relapse high risk langerhans cell histiocytosis with the combination of cytarabine, vindesine and prednisone.
Wang W; Ge J; Ma H; Lian H; Cui L; Zhao Y; Li Z; Wang T; Zhang R
BMC Pediatr; 2024 Jan; 24(1):1. PubMed ID: 38172736
[TBL] [Abstract][Full Text] [Related]
3. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
4. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
[No Abstract] [Full Text] [Related]
5. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
Wu FF; Gao YJ; Pan C; Chen J; Tang JY
Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
Wang D; Chen XH; Wei A; Zhou CJ; Zhang X; Ma HH; Lian HY; Zhang L; Zhang Q; Huang XT; Wang CJ; Yang Y; Liu W; Wang TY; Li ZG; Cui L; Zhang R
Orphanet J Rare Dis; 2022 Apr; 17(1):151. PubMed ID: 35379272
[TBL] [Abstract][Full Text] [Related]
7. Clinical features and treatment outcomes of liver involvement in paediatric Langerhans cell histiocytosis.
Ge X; Ou W; Wei A; Lian H; Ma H; Cui L; Wang D; Zhang L; Wang X; He L; Zhang R; Wang T
BMC Pediatr; 2024 May; 24(1):316. PubMed ID: 38714959
[TBL] [Abstract][Full Text] [Related]
8. Pediatric langerhans cell histiocytosis: single center experience over a 17-year period.
İnce D; Demirağ B; Özek G; Erbay A; Ortaç R; Oymak Y; Kamer S; Yaman Y; Kundak S; Vergin C
Turk J Pediatr; 2016; 58(4):349-355. PubMed ID: 28276205
[TBL] [Abstract][Full Text] [Related]
9. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.
Gadner H; Grois N; Pötschger U; Minkov M; Aricò M; Braier J; Broadbent V; Donadieu J; Henter JI; McCarter R; Ladisch S;
Blood; 2008 Mar; 111(5):2556-62. PubMed ID: 18089850
[TBL] [Abstract][Full Text] [Related]
10. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
[TBL] [Abstract][Full Text] [Related]
11. Comparison of vindesine and prednisone and cyclophosphamide, etoposide, vindesine, and prednisone as first-line treatment for adult Langerhans cell histiocytosis: A single-center retrospective study.
Duan MH; Han X; Li J; Zhang W; Zhu TN; Han B; Zhuang JL; Wang SJ; Cao XX; Cai HC; Chen M; Yang C; Zhou DB
Leuk Res; 2016 Mar; 42():43-6. PubMed ID: 26859782
[TBL] [Abstract][Full Text] [Related]
12. Second-line regimen for CNS-involved pediatric Langerhans cell histiocytosis.
Lian H; Cui L; Yang Y; Wei A; Cheng H; Li N; Zhang L; Ma H; Zhao X; Wang T; Li Z; Zhang R
Pituitary; 2022 Feb; 25(1):108-115. PubMed ID: 34302575
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis.
Cao XX; Duan MH; Zhao AL; Cai H; Chen J; Gao XM; Liu T; Cai HC; Zhang L; Sun J; Liang ZY; Zhou DB; Li J
Am J Hematol; 2022 Feb; 97(2):203-208. PubMed ID: 34797941
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
Narula G; Pradhan ND; Arora B; Banavali SD
Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
[TBL] [Abstract][Full Text] [Related]
15. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
[No Abstract] [Full Text] [Related]
16. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years' experience of 154 patients at a single center.
Lee JW; Shin HY; Kang HJ; Kim H; Park JD; Park KD; Kim HS; Park SH; Wang KC; Ahn HS
Pediatr Hematol Oncol; 2014 Apr; 31(3):293-302. PubMed ID: 24397251
[TBL] [Abstract][Full Text] [Related]
18. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
Morimoto A; Shioda Y; Kudo K; Kanegane H; Imamura T; Koh K; Kosaka Y; Yuza Y; Nakazawa A; Saito AM; Watanabe T; Nakazawa Y
Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
[TBL] [Abstract][Full Text] [Related]
19. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
Minkov M
Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group.
Monsereenusorn C; Suwannaying K; Techavichit P; Sathitsamitphong L; Komvilaisak P; Rujkijyanont P; Seksarn P; Charoenkwan P; Pakakasama S
Int J Hematol; 2022 Apr; 115(4):563-574. PubMed ID: 35099760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
